New cancer drug candidate enters early human testing

NCT ID NCT05006794

Terminated Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new oral drug called zamzetoclax (GS-9716) in about 145 people with advanced solid tumors. The drug is given alone or combined with standard chemotherapies. The main goals are to find the safest dose and understand side effects. This is a safety study, not yet designed to prove the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zamzetoclax (GS-9716), a drug taken orally, tested alone or with chemotherapy drugs docetaxel or sacituzumab govitecan-hziy
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not on effectiveness. Many drugs fail at this stage, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID MALIGNANCIES

Contacts and locations

Locations

Hadassah Medical Center- Ein Kerem

Jerusalem, 91120, Israel
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Montefiore Medial Center - Montefiore Medical Park

The Bronx, New York, 10467, United States
Novant Health Cancer Institute - Elizabeth (Breast Cancer)

Charlotte, North Carolina, 28204, United States
Oregon Health Oregon Health & Sciences University-Knight Cancer Institute

Portland, Oregon, 97239, United States
Rambam Health Care Campus

Haifa, 31096, Israel
START Midwest

Grand Rapids, Michigan, 49546, United States
START Mountain Region

West Valley City, Utah, 84119, United States
START San Antonio

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
Tel-Aviv Sourasky Medical Center

Tel Aviv, 6423906, Israel
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.